OPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
OptimizeRx Corp (OPRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown some positive financial performance in Q4 2025, including exceeding market expectations on EBITDA and EPS, the overall financial trends, technical indicators, and analyst sentiment suggest caution. The stock lacks strong upward momentum, and there are no significant trading signals or catalysts to suggest immediate upside potential. A hold strategy is recommended until more favorable conditions emerge.
The MACD is positive and expanding, indicating some bullish momentum, but the RSI is neutral at 38.902, providing no clear signal. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key resistance levels (R1: 8.542, R2: 9.014) with support at S1: 7.014. Overall, the technical indicators suggest a weak trend with no strong buy signal.
The company exceeded Q4 2025 market expectations for revenue, EBITDA, and non-GAAP EPS. Gross margin improved to 74.8%, and the Board authorized a $10 million share repurchase program, signaling confidence in the stock.
is also in decline (-0.84%).
In Q4 2025, revenue slightly declined by -0.24% YoY to $32.2 million. Net income dropped significantly by -6535.90% YoY to $5.02 million. However, EPS remained flat at $0.26 YoY, and gross margin improved by 10.27% YoY to 74.8%.
Stephens analyst Jeff Garro lowered the price target to $10 from $17, maintaining an Equal Weight rating. While the analyst notes confidence in customer engagement and potential budget unlocks in the second half, they remain cautious and patient about validating this rebound.
